当前位置:首页 - 行情中心 - 奥翔药业(603229) - 财务分析 - 现金流量表

奥翔药业

(603229)

  

流通市值:67.34亿  总市值:67.34亿
流通股本:8.30亿   总股本:8.30亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金268,793,451.83124,035,737.44881,351,859.33659,187,022.28
  收到的税费返还16,069,012.47143,941.881,727,029.7-
  收到其他与经营活动有关的现金64,643,012.5664,200,585.02101,167,997.760,824,871.6
  经营活动现金流入小计349,505,476.86188,380,264.34984,246,886.73720,011,893.88
  购买商品、接受劳务支付的现金194,886,416.999,316,564.87377,408,767.45294,171,951.15
  支付给职工以及为职工支付的现金133,817,508.3876,515,403.1211,547,810.19165,425,717.97
  支付的各项税费24,034,419.744,635,845.7542,615,285.8941,043,301.08
  支付其他与经营活动有关的现金39,130,384.4341,947,428.61196,166,108.9571,725,311.31
  经营活动现金流出小计391,868,729.45222,415,242.33827,737,972.48572,366,281.51
  经营活动产生的现金流量净额-42,363,252.59-34,034,977.99156,508,914.25147,645,612.37
二、投资活动产生的现金流量:
  取得投资收益收到的现金---19,243,464.16
  处置固定资产、无形资产和其他长期资产收回的现金净额--109,013.45282,596.09
  收到的其他与投资活动有关的现金29,446,426.648,887,293.0866,925,007.5228,562,110.52
  投资活动现金流入小计29,446,426.648,887,293.0867,034,020.9748,088,170.77
  购建固定资产、无形资产和其他长期资产支付的现金45,446,809.5625,228,160.11104,445,390.3481,485,874.15
  投资支付的现金---4,008,816
  支付其他与投资活动有关的现金8,976,423.144,951,851.5721,011,807.9910,431,265.02
  投资活动现金流出小计54,423,232.730,180,011.68125,457,198.3395,925,955.17
  投资活动产生的现金流量净额-24,976,806.06-21,292,718.6-58,423,177.36-47,837,784.4
三、筹资活动产生的现金流量:
  取得借款收到的现金215,018,040101,000,000505,180,810.84275,180,810.84
  收到其他与筹资活动有关的现金1,357,855.24602,116.4819,336,915.632,715,711.71
  筹资活动现金流入小计216,375,895.24101,602,116.48524,517,726.44307,896,522.55
  偿还债务支付的现金309,445,810.8471,045,810.84320,355,000170,294,767.18
  分配股利、利润或偿付利息支付的现金5,631,968.83,337,074.7190,623,943.6288,318,438.42
  支付其他与筹资活动有关的现金16,236,603.9419,589,149.3863,087,428.2114,400,313.33
  筹资活动现金流出小计331,314,383.5893,972,034.93474,066,371.82373,013,518.93
  筹资活动产生的现金流量净额-114,938,488.347,630,081.5550,451,354.62-65,116,996.38
四、汇率变动对现金及现金等价物的影响-33,254,046.82-22,048,408.04-17,457,141.89-2,547,447.62
五、现金及现金等价物净增加额-215,532,593.81-69,746,023.08131,079,949.6232,143,383.97
  加:期初现金及现金等价物余额1,179,661,168.771,179,661,168.771,048,581,219.151,048,581,219.15
  期末现金及现金等价物余额964,128,574.961,109,915,145.691,179,661,168.771,080,724,603.12
补充资料:
  净利润119,840,785.42-130,570,123.6-
  资产减值准备2,186,481.64-19,583,678.95-
  固定资产和投资性房地产折旧40,914,003.9-72,038,987.35-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧40,914,003.9-72,038,987.35-
  无形资产摊销1,033,872.64-2,150,081.02-
  固定资产报废损失--1,482,914.86-
  公允价值变动损失-26,427,338.21-489,448.22-
  财务费用43,104,744.34-28,695,012.24-
  投资损失-10,766,110.31--22,281,446.94-
  递延所得税-3,908,236.68--3,359,175.1-
  其中:递延所得税资产减少-3,908,236.68--3,359,175.1-
  存货的减少26,324,440.16--16,934,028.94-
  经营性应收项目的减少-333,524,777.94--9,119,596.86-
  经营性应付项目的增加83,232,095.19--42,401,299.36-
  其他---87,556.43-
  现金的期末余额964,128,574.96-1,179,661,168.77-
  减:现金的期初余额1,179,661,168.77-1,048,581,219.15-
  现金及现金等价物的净增加额-215,532,593.81-131,079,949.62-
公告日期2026-08-292026-04-292026-04-292025-10-31
审计意见(境内)标准无保留意见
TOP↑